Your trusted source for investing success
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
By Pia Rivera
HTG Molecular Diagnostics leads the list of last week’s life science gainers on the NASDAQ, followed by La Jolla Pharmaceutical, Dynavax Technologies, NewLink Genetics and BioCryst Pharmaceutical.
By Pia Rivera
Here’s a closer look at last week’s top gainers.
By Pia Rivera
EnteroMedics leads the list of last week’s lifescience gainers on the NASDAQ, followed by Calithera Biosciences, Halozyme Therapeutics, Immunogen, and Vermillion.
Through the rise of bioelectronics and medtech, medical device manufacturers are claiming major market share.
From cybersecurity to bioelectronics, medical device topics are garnering increased media coverage.
Although comments from President-elect Donald Trump triggered a fall of 2.92 percent on Wednesday, the index bounced back toward the end of the week.
We’re examining the TSX’s five top gainers in the realm of the pharmaceuticals, biotech and medical devices. What’s behind their stock movement?
A class action lawsuit filed against medical device manufacturer Neovasc was dismissed on November 23, 2016.
We’re looking ahead to some innovative medical devices arriving in 2017 and beyond—namely, a series of ‘artificial organs’ that imitate a key bodily function.
St. Jude Medical, a global medical device company, today presented favorable results from the largest observational study to date of the company’s AMPLATZER™ Amulet™ left atrial appendage occluder.
Short seller Muddy Waters Capital has reiterated allegations of cybersecurity vulnerability with St. Jude Medical’s cardiac devices.
